Lisa Schweizer, Rahul Krishnan, Aasa Shimizu, Andreas Metousis, Hilary Kenny, Rachelle Mendoza, Thierry M Nordmann, Sarah Rauch, Lucy Kelliher, Janna Heide, Florian A Rosenberger, Agnes Bilecz, Sanaa Nakad Borrego, Maximillian T Strauss, Marvin Thielert, Edwin Rodriguez, Johannes B Müller-Reif, Mengjie Chen, S Diane Yamada, Andreas Mund, Ricardo R Lastra, Matthias Mann, Ernst Lengyel
Serous borderline tumors (SBT) are epithelial neoplastic lesions of the ovaries that commonly have a good prognosis. In 10-15% of cases, however, SBT will recur as low-grade serous cancer (LGSC), which is deeply invasive and responds poorly to current standard chemotherapy 1,2,3 . While genetic alterations suggest a common origin, the transition from SBT to LGSC remains poorly understood 4 . Here, we integrate spatial proteomics 5 with spatial transcriptomics to elucidate the evolution from SBT to LGSC and its corresponding metastasis at the molecular level in both the stroma and the tumor...
November 13, 2023: medRxiv